By Joseph Walker
Neumora Therapeutics shares plunged more than 80% on Thursday after its lead drug candidate failed to help patients with depression in a study.
The drug, called navacaprant, was no better than a placebo in the trial, the first of three Phase 3 studies the company is running in hopes of gaining U.S. approval.
"Today's readout represents a worst-case scenario for the program," said RBC Capital Markets analyst Brian Abrahams in a note to clients.
Neumora shares fell 81% to $2.00 in early trading.
The company said it has cash of $342 million that will allow it to survive into at least mid-2026.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
January 02, 2025 11:03 ET (16:03 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.